Recently Featured

Roche KRAS drug succeeds in head-to-head lung cancer study

August 8, 2026
The Phase 3 trial comparing Roche’s divarasib with treatments from Amgen and Bristol Myers in patients with non-small cell lung cancer has yielded promising results, indicating a significant advancement in targeted therapies for this challenging indication. This head-to-head study not only highlights the efficacy of divarasib but also underscores Roche’s commitment to pioneering innovative solutions…

EMA Intensifies Focus on Women’s Health in Medicines Development

August 8, 2026
The European Medicines Agency (EMA) is intensifying its efforts to integrate women’s health considerations into the development and regulation of medicines. This initiative comes in response to the recognition that women, who generally have a longer life expectancy than men, often face unique health challenges that have historically been underrepresented in clinical research and regulatory…

Ipsen bolsters rare disease pipeline in €700m Memo takeover

August 8, 2026
Ipsen has announced its acquisition of Memo for €700 million, marking a significant expansion of its rare disease pipeline. This acquisition is notable as it follows closely on the heels of Ipsen’s recent purchase of Kartos, completed on June 29, which further underscores the company’s aggressive strategy in the rare disease sector. The move comes…

Peptistar Begins Operation of Asahi Kasei’s FO-MD System at Manufacturing Scale

August 7, 2026
Japanese CDMO Peptistar has commenced the operation of Asahi Kasei’s forward osmosis–membrane distillation (FO–MD) system for the trial production of active pharmaceutical ingredients (APIs). This innovative system, first announced by Asahi Kasei in 2018, allows for the dehydration and concentration of liquids without the need for heat or pressure, significantly reducing the time required for…

Ongoing Cases